A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.
He who hesitates may be lost, but when it comes to testifying about drug pricing, it appears that there is some benefit in putting it off as long as possible.
For AbbVie Inc., at least, it appears to have worked out that way after the company’s CEO, Richard Gonzalez,...
The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.
Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.
A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.
Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.
